[1]贾 斐,辛 超,周 欢.活动性肺结核患者血清中RNase E ，HupB表达水平与疗效及病情预后的关系[J].现代检验医学杂志,2025,40(01):78-83.[doi:10.3969/j.issn.1671-7414.2025.01.015]
　JIA Fei,XIN Chao,ZHOU Huan.Expression Levels of Serum RNase E , HupB of Patients with Active Pulmonary Tuberculosis and Their Relationship with Curative Effect and Prognosis[J].Journal of Modern Laboratory Medicine,2025,40(01):78-83.[doi:10.3969/j.issn.1671-7414.2025.01.015]
点击复制

活动性肺结核患者血清中RNase E ，HupB表达水平与疗效及病情预后的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
78-83
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Expression Levels of Serum RNase E , HupB of Patients with Active Pulmonary Tuberculosis and Their Relationship with Curative Effect and Prognosis
文章编号:
1671-7414（2025）01-078-06
作者:
贾 斐; 辛 超; 周 欢
（陕西省结核病防治院内七科，西安 710100）
Author(s):
JIA Fei; XIN Chao; ZHOU Huan
(Departments of Seven Medicine，Tuberculosis Prevention and Treatment Hospital of Shaanxi Province，Xi’an 710100, China)
关键词:
活动性肺结核; 核糖核酸酶; HupB
分类号:
R521；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.01.015
文献标志码:
A
摘要:
目的 探讨活动性肺结核(APTB）患者血清中核糖核酸酶E（RNase E）、HupB 表达水平与患者治疗效果及病情预后的关系。方法 选择2020 年3 月～ 2023 年3 月陕西省结核病防治院收治的108 例APTB 患者（APTB组）和101 例非APTB 患者（对照组）。所有APTB 患者接受抗结核治疗，统计治疗后病情转归和复发情况，根据治疗结束后结核分枝杆菌控制情况将患者分为转归组（n=73）和未转归组（n=35）；根据复发情况将患者分为复发组（n=22）和未复发组（n=86）。检测各组血清RNase E 和HupB 蛋白水平。多因素Logistic 回归分析影响APTB 患者复发的因素，受试者工作特征（ROC）曲线分析血清RNase E 和HupB 预测ATPB 复发的价值。结果 APTB 组血清RNase E（213.02±55.16 pg/ml）和HupB 蛋白（853.26±262.19μg/ml）水平高于对照组（102.35±24.09pg/ml，412.51±103.65μg/ml），差异具有统计学意义（t=26.368，15.779，均P ＜ 0.05）。未转归组治疗前后血清RNase E（247.79±20.05 pg/ml，239.46±18.43 pg/ml）和HupB 蛋白（970.92±71.26 μg/ml，952.34±65.08 μg/ml）水平高于转归组（196.35±13.46 pg/ml，121.42±10.02 pg/ml；796.85±65.43 μg/ml，512.05±33.67 μg/ml），差异具有统计学意义（t=15.761，43.137；12.570，46.417，均P＜ 0.05）；复发组血清RNase E（250.32±16.74 pg/ml）和HupB蛋白（991.32±102.46μg/ml ）水平高于未复发组（203.48±21.35 pg/ml，817.94±62.35 μg/ml），差异具有统计学意义（t=9.554，10.066，均P＜ 0.05）。多因素Logistic 回归分析显示治疗未转归［OR（95%CI）：3.865（1.417 ～ 10.544）］、高血清RNase E［OR（95%CI）：2.330（1.096 ～ 4.956）］和HupB 蛋白［OR（95%CI）：1.702（1.144 ～ 2.534）］是APTB 复发的危险因素（均P ＜ 0.05）。RNase E 和HupB 联合预测ATPB 复发的AUC（95%CI）为0.872（0.793 ～ 0.928），高于RNase E［0.779（0.689 ～ 0.853）］和HupB［0.719（0.624 ～ 0.801）］单独预测，差异具有统计学意义（Z=1.981，2.125，均P ＜ 0.05）。结论 ATPB患者血清RNase E 和HupB 蛋白水平均显著增高，且与病情转归及复发有关，可作为ATPB 预后的标志物。
Abstract:
Objective To explore the relationship between the expression levels of serum ribonuclease E (RNase E) and HupB of patients with active pulmonary tuberculosis (APTB) and their treatment efficacy and prognosis. Methods From March 2020 to March 2023, 108 patients with APTB (APTB group) and 101 patients without APTB (control group) were selected from the Tuberculosis Prevention and Treatment Hospital of Shanxi Province. All APTB patients received anti-tuberculosis treatment, and the prognosis and recurrence of the disease were statistically analyzed. Based on the control of Mycobacterium tuberculosis after treatment, the patients were divided into a conversion group (n=73) and a non-conversion group (n=35). According to the recurrence situation, patients were divided into the recurrence group (n=22) and the non-recurrence group (n=86). Serum RNase E and HupB protein levels were detected in each group. Multivariate logistic regression analysis was used to identify the factors that affect the recurrence of APTB patients, and ROC curve analysis was used to assess the value of serum RNase E and HupB in predicting ATPB recurrence. Results The levels of serum RNase E (213.02±55.16pg/ml) and HupB protein (853.26±262.19μg/ ml) in the APTB group were higher than those in the control group（102.35±24.09pg/ml，412.51±103.65μg/ml）, the differences were statistically significant (t=26.368, 15.779, all P<0.05). Before and after treatment, the levels of serum RNase E(247.79±20.05pg/ml，239.46±18.43pg/ml) and HupB protein(970.92±71.26μg/ml，952.34±65.08μg/ml) in the nonconversion group were higher than those in the conversion group（196.35±13.46 pg/ml，121.42±10.02 pg/ml；796.85±65.43 μg/ml，512.05±33.67 μg/ml）, the differences were statistically significant (t=15.761，43.137；12.570，46.417，all P<0.05). The levels of serum RNase E(250.32±16.74pg/ml) and HupB protein(991.32±102.46μg/ml) in the recurrence group were higher than those in the non-recurrence group（203.48±21.35 pg/ml，817.94±62.35 μg/ml）, the differences were statistically significant (t=9.554，10.066，all P<0.05). Multivariate Logistic regression analysis showed that no outcome of treatment［OR （95%CI）：3.865（1.417 ～ 10.544）］, high serum RNase E［(OR(95%CI)：2.330（1.096 ～ 4.956)］ and HupB protein［OR （95%CI）：1.702（1.144 ～ 2.534）］levels were risk factors for APTB recurrence (all P < 0.05). The AUC（95%CI） predicted by the combination of RNase E and HupB for ATPB recurrence was 0.872（0.793 ～ 0.928）, higher than that predicted by RNase E［0.779（0.689 ～ 0.853）］and HupB alone［0.719（0.624 ～ 0.801）］, the differences were statistically significant (Z=1.981, 2.125, all P<0.05). Conclusion The serum RNase E and HupB protein levels in patients with ATPB are significantly increased and are associated with disease progression and recurrence, which can serve as prognostic markers for ATPB.

参考文献/References:

[1] HAN Dong, HE Taiping, YU Yong, et al. Diagnosis of active pulmonary tuberculosis and community acquired pneumonia using convolution neural network based on transfer learning[J]. Academic Radiology, 2022, 29(10): 1486-1492.
[2] ZIMMER A J , LAINATI F, AGUILERA VASQUEZ N，et al. Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis [J]. Journal of Clinical Microbiology, 2022, 60(2): e0185921.
[3] P?OCI?SKI P, MACIOS M, HOUGHTON J, et al. Proteomic and transcriptomic experiments reveal an essential role of RNA degradosome complexes in shaping the transcriptome of Mycobacterium tuberculosis[J]. Nucleic Acids Research, 2019, 47(11): 5892-5905.
[4] YU Xiaoli, JIANG Shengsheng, LI Yang, et al. Development of a new cellular immunological detection method for tuberculosis based on HupB protein induced IL-6 release test [J]. Frontiers in Microbiology, 2023, 14: 1148503.
[5] 中华人民共和国国家卫生和计划生育委员会.WS288-2017 肺结核诊断 [S].( 2017-11-09)［2018-05-01］http://www.nhc.gov.cn/wjw/s9491/201712/a45 2586fd21d4018b0ebc00b89c06254.shtml. National Health and Family Planning Commission of the People’s Republic of China. WS288-2017: Diagnosis for pulmonary tuberculosis [S]( 2017-11-09)［2018-05-01］ http://www.nhc.gov.cn/wjw/s9491/201712/a452586fd21d 4018b0ebc00b89c06254.shtml.
[6] RABAAN A A, MUTAIR A A, ALBAYAT H, et al. Tools to alleviate the drug resistance in Mycobacterium tuberculosis[J]. Molecules, 2022, 27(20): 6985.
[7] BESPYATYKH J, SHITIKOV E, BESPIATYKH D, et al. Metabolic changes of Mycobacterium tuberculosis during the anti-tuberculosis therapy[J]. Pathogens, 2020, 9(2): 131.
[8] 梁津, 刘轾彬, 梁成员, 等. 初诊活动性肺结核患者血浆IL-6，IL-17，IL-37 及TIM-3 水平表达及其临床意义[J]. 现代检验医学杂志,2021,36(6):179-182. LIANG Jin, LIU Zhibin, LIANG Chengyuan, et al. Expression and clinical significance of plasma IL-6, IL-17, IL-37 and TIM-3 in patients with newly diagnosed active pulmonary tuberculosis[J]. Journal of Modern Laboratory Medicine, 2021, 36(6): 179-182.
[9] LIU Dongxin, HUANG Fei, ZHANG Guoliang, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China[J]. Clinical Microbiology and Infection, 2022, 28(5): 731.e9-731.e15.
[10] MZINZA D T, SLOAN D J, JAMBO K C, et al. Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis [J]. Tuberculosis (Edinburgh, Scotland), 2015, 95(4): 463-469.
[11] MACKIE G A. RNase E: at the interface of bacterial RNA processing and decay[J]. Nature Reviews Microbiology, 2013, 11(1): 45-57.
[12] LAALAMI S, CAVAIUOLO M, ROQUE S, et al. Escherichia coli RNase E can efficiently replace RNase Y in Bacillus subtilis [J]. Nucleic Acids Research, 2021, 49(8): 4643-4654.
[13] LEE J, SHIN E, YEOM J H, et al. Regulator of RNase E activity modulates the pathogenicity of Salmonella typhimurium[J].Microbial Pathogenesis, 2022, 165: 105460.
[14] ZHOU Ying, SUN Huaming, RAPIEJKO A R, et al. Mycobacterial RNase E cleaves with a distinct sequence preference and controls the degradation rates of most Mycolicibacterium smegmatis mRNAs [J]. Journal of Biological Chemistry, 2023, 299(11): 105312.
[15] HUGHES D. Using the power of genetic suppressors to probe the essential functions of RNase E[J]. Current Genetics, 2016, 62(1): 53-57.
[16] IFILL G, BLIMKIE T, LEE A H Y, et al. RNase III and RNase E influence posttranscriptional regulatory networks involved in virulence factor production, metabolism, and regulatory RNA processing in Bordetella pertussis[J]. mSphere, 2021, 6(4): e0065021.
[17] MARDLE C E, GODDARD L R, SPELMAN B C, et al. Identification and analysis of novel small molecule inhibitors of RNase E: implications for antibacterial targeting and regulation of RNase E [J]. Biochemistry and Biophysics Reports, 2020, 23: 100773.
[18] SANCHEZ-GARRIDO J, RUANO-GALLEGO D, CHOUDHARY J S, et al. The type III secretion system effector network hypothesis[J]. Trends in Microbiology, 2022, 30(6): 524-533.
[19] GREEN K D, BISWAS T, PANG A H, et al. Acetylation by Eis and deacetylation by Rv1151c of Mycobacterium tuberculosis HupB: biochemical and structural insight[J]. Biochemistry, 2018, 57(5): 781-790.
[20] GRIEGO A, DOUCH? T, GIANETTO Q G, et al. RNase E and HupB dynamics foster mycobacterial cell homeostasis and fitness[J]. iScience, 2022, 25(5): 104233.
[21] CHOUDHURY M, VIRIVINTI J, KANDI S, et al. Th2 immune response by the iron-regulated protein HupB of Mycobacterium tuberculosis[J]. the Indian Journal of Tuberculosis, 2022, 69(1): 90-99.
[22] SINGH N, SHARMA N, SINGH P, et al. HupB, a nucleoid-associated protein, is critical for survival of Mycobacterium tuberculosis under host-mediated stresses and for enhanced tolerance to key first-line antibiotics [J]. Frontiers in Microbiology, 2022, 13:937970.

备注/Memo

备注/Memo:
基金项目：陕西省科学技术研究发展计划（2020JM4160）。
作者简介：贾斐（1988-），女，本科，主治医师，研究方向：结核病的诊治，E-mail：jiafei8349@126.com。
通讯作者：周欢（1988-），女，本科，主治医师，研究方向：结核病的诊治，E-mail：116298989@qq.com。
更新日期/Last Update: 2025-01-15